Danaparoid Sodium for Heparin Induced Thrombocytopenia (HITSOVA Trial)

"Danaparoid Sodium was first trialed in 2019 at the Regional Hospital after N.N Burdenko. There have been a total of 12 completed clinical trials since then, with 5 ongoing studies. A majority of these investigations are taking place in Ottawa, Ontario."

"This study is enrolling patients at The Ottawa Hospital; 501 Smyth Road in Ottawa, Ontario, Hamilton General Hospital in Hamilton, Ohio, and The Ohio State University Wexner Medical Center in Columbus as well as other sites 9 other locations."

"Danaparoid Sodium is considered safe based on its status as a Phase 3 clinical trial drug. This classification means that, while there is some efficacy data available, the focus has been on multiple rounds of safety testing."

"As of right now, there are 5 ongoing studies for Danaparoid Sodium in 94 different cities and 12 nations. The first ever clinical trial occurred in 2019 and was completed by Aspen Global Incorporated. In total, 508 patients were observed during the Phase 3 stage of drug approval. Since that time, an additional 12 trials have been conducted."

"This trial has completed patient recruitment. According to the information on clinicaltrials.gov, The study was posted on 5/16/2019 and updated for the last time on 7/19/2022. There are currently 123 other trials enrolling patients with heparin-induced thrombocytopenia and 5 studies involving Danaparoid Sodium that are actively looking for candidates."

"Eligibility for this study begins at 2 weeks old and extends to 100 years of age."

"This trial is looking for 508 participants with heparin-induced thrombocytopenia aged 2 weeks to 100. The most important criteria for applicants are as follows: they must not be a woman of childbearing potential, or a woman of childbearing potential who agrees to follow the contraceptive guidance during the treatment period and during the entire VKA use and for one month after cessation of its use; subjects should continue with adequate contraception after the study end if they continue with VKA use. (Subjects taking oral contraceptives or hormone replacement therapy must have a stable dose and regimen for ≥ 3 months prior to entry into"

"Danaparoid Sodium is a medication used to treat deep vein thrombosis. It can also help prevent deep vein thrombosis caused by orthopedic surgery and percutaneous coronary intervention (pci)."